All stock lists
DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
US · Delayed Price · Currency is USD
Also listed: 0I8F.L, DY2.DE, DY2.FHealthcare · Medical - Instruments & Supplies
9.22-0.21 (-2.23%)
Market cap
$1.84B
Health Score
Analyst consensus
Listed since
Aug 12, 1987
Website
Insider Score
––Not scored
XRAY Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
XRAY analyst forecast
XRAY analyst consensus
Hold6 ratings
Buy 1 Hold 4 Sell 1
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
XRAY 12-month price target
$10.00+8.5% upsideaverage of 1 firm
$10.00High
$10.00Low
Best analysts covering XRAY
- Barrington Research0%success rate · 12 calls
- UBS0%success rate · 4 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
XRAY analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-10-26 |
| — | Mizuho | Neutral | — | — | Reiterated | 2026-10-22 |
| — | Leerink Partners | Market Perform | — | — | Reiterated | 2026-10-14 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2026-10-09 |
| BMO Capital | Market Perform | $10.00 | -1.4% | Reiterated | 2026-09-17 | |
| — | Barclays | Underweight | — | — | Reiterated | 2026-08-24 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2026-07-29 |
| — | Barclays | Underweight | — | — | Reiterated | 2026-06-04 |
| — | UBS | Buy | — | — | Reiterated | 2026-05-07 |
| — | Mizuho | Neutral | — | — | Reiterated | 2026-05-06 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-03-02 |
| — | Mizuho | Neutral | — | — | Reiterated | 2026-03-02 |
| — | Evercore ISI Group | In Line | — | — | Reiterated | 2026-02-27 |
| — | Wells Fargo | Equal Weight | — | — | Reiterated | 2026-02-27 |
| — | Baird | Neutral | — | — | Reiterated | 2026-02-27 |
| — | B of A Securities | Buy | — | — | Upgraded | 2026-02-19 |
| — | UBS | Buy | — | — | Reiterated | 2026-02-03 |
| — | Mizuho | Neutral | — | — | Reiterated | 2026-01-20 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2026-01-05 |
| — | Baird | Neutral | — | — | Reiterated | 2025-12-16 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-12-16 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-11-10 |
| — | William Blair | Market Perform | — | — | Downgraded | 2025-11-07 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-11-07 |
| — | Wells Fargo | Equal Weight | — | — | Reiterated | 2025-11-07 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-10-29 |
| — | UBS | Buy | — | — | Reiterated | 2025-10-28 |
| — | Evercore ISI Group | In Line | — | — | Reiterated | 2025-10-08 |
| — | Needham | Hold | — | — | Reiterated | 2025-09-26 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-08-08 |
| — | Wells Fargo | Equal Weight | — | — | Reiterated | 2025-08-08 |
| — | Stifel | Hold | — | — | Reiterated | 2025-08-08 |
| — | UBS | Buy | — | — | Reiterated | 2025-08-08 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-07-22 |
| — | Needham | Hold | — | — | Reiterated | 2025-07-21 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-05-12 |
| — | UBS | Buy | — | — | Reiterated | 2025-05-09 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2025-04-30 |
| — | Mizuho | Neutral | — | — | Reiterated | 2025-03-13 |
| — | Needham | Hold | — | — | Downgraded | 2025-03-13 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2025-02-28 |
| — | Wells Fargo | Equal Weight | — | — | Reiterated | 2025-02-28 |
| — | Baird | Neutral | — | — | Reiterated | 2025-02-28 |
| — | Needham | Buy | — | — | Reiterated | 2025-02-28 |
| — | Needham | Buy | — | — | Reiterated | 2025-02-11 |
| — | Needham | Buy | — | — | Reiterated | 2025-01-30 |
| — | Jefferies | Hold | — | — | Downgraded | 2025-01-23 |
| — | Evercore ISI Group | In Line | — | — | Downgraded | 2025-01-07 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2024-12-17 |
| — | UBS | Buy | — | — | Reiterated | 2024-12-03 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-11-08 |
| — | Baird | Neutral | — | — | Reiterated | 2024-11-08 |
| — | Leerink Partners | Market Perform | — | — | Downgraded | 2024-11-07 |
| — | Needham | Buy | — | — | Reiterated | 2024-10-28 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2024-10-08 |
| — | Barrington Research | Outperform | — | — | Reiterated | 2024-09-20 |
| — | Needham | Buy | — | — | Reiterated | 2024-08-20 |
| — | Needham | Buy | — | — | Reiterated | 2024-07-31 |
| — | Baird | Neutral | — | — | Reiterated | 2024-07-22 |
| — | Stifel | Hold | — | — | Reiterated | 2024-07-18 |
XRAY earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-26 | 0.28 | 0.27 | $926.2M | $961.0M |
| 2026-05-05 | 0.28 | 0.27 | $841.8M | $880.0M |
| 2026-08-06 | 0.35 | 0.52 | $889.9M | $898.0M |
| 2026-11-05 | 0.31 | 0.00 | $861.6M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.